Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In December 2023, Gilead Sciences announced an agreement with Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, a high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth
Lysosomal cysteine cathepsins B and L are often overexpressed in aggressive tumors, and upon their transfer to the invadosomes and following secretion to the extracellular space, they can participate in the degradation of the extracellular matrix [46, 48]
Woodell-May, J
Adequate selenium intake is mandatory for the normal function of thyrocytes, and selenium deficiency is associated with the decreased synthesis of thyroid hormones (191), increased thyroid volume, and increased number of thyroid nodules (182, 192)
